Reverse Takeover in Switzerland.
How a private company in Switzerland can go public in the United States by reverse takeover into a clean Nasdaq, NYSE American or OTC shell — and the home-market considerations that shape the transaction.
Switzerland concentrates an outsized share of global life-sciences, precision-technology and financial talent in a small, stable and export-driven economy. The SIX Swiss Exchange is a respected home for pharmaceutical majors and established industrials, but smaller Swiss innovators — particularly in drug development and deep tech — often find US public investors better matched to their capital needs. A reverse takeover, folding a private Swiss company into a listed Nasdaq, NYSE American or OTC shell, offers a structured route to a dollar quote and a global shareholder base without the demands of a full underwritten IPO.
- Swiss Code of Obligations accounts, and any Swiss GAAP FER or group IFRS, need restatement and re-audit to PCAOB standards — usually the timetable-defining task.
- Cantonal tax practice varies, so an advance Swiss tax ruling on the reorganisation and holding structure is commonly obtained.
- Swiss withholding tax and stamp-duty considerations, plus the Switzerland–US treaty and PFIC exposure, warrant early specialist review.
- A Swiss holding company can often be used directly, potentially avoiding an offshore topco that other jurisdictions require.
- Any parallel SIX Swiss Exchange ambitions should be reconciled with the US listing path before the merger is structured.
Switzerland at a glance
| Home market | SIX Swiss Exchange |
|---|---|
| Home regulator | Swiss Financial Market Supervisory Authority (FINMA) |
| Currency | Swiss franc (CHF) |
| Notable sectors | Life sciences and pharma, precision technology, fintech, and consumer. |
| US venues | Nasdaq, NYSE American, and the OTC Markets (OTCQX, OTCQB) |
| Our role | Advisory and arranger of the reverse takeover; not a broker-dealer, law firm or auditor. |
Why Switzerland companies list in the United States
Swiss companies turn to the United States for the depth of its specialist life-sciences and technology capital and for valuations that reward long-development-cycle science on its forward potential. A US listing gives a franc-earning group a dollar acquisition currency for building scale in its largest market and an analyst following tuned to biotech and precision-technology stories. Switzerland’s pharma and medtech ecosystem around Basel, Zurich and Lake Geneva produces exactly the categories US thematic funds pursue, and Swiss founders often already run globally distributed operations that sit naturally under a US-listed parent. A reverse takeover reaches that investor base on a defined timetable, a practical alternative when the pool for smaller Swiss growth issuers is thin at home.
The Switzerland market and a US listing
Domestically, companies list on the SIX Swiss Exchange, a self-regulated venue with high governance standards and strong coverage of large caps under FINMA’s market oversight. SIX serves flagship pharmaceutical and industrial issuers superbly, but analyst attention and liquidity for smaller life-sciences and technology names can be limited relative to a dedicated US venue. A US reverse takeover differs in mechanics: rather than a SIX listing prospectus, the route runs through SEC disclosure, a public float and, for Nasdaq, a minimum US$4.00 bid price. For a globally oriented Swiss innovator, the trade is access to deeper, more specialised capital, while a domestically anchored group may still find SIX the better fit.
Sectors driving Switzerland US listings
Switzerland’s defining sectors for US public markets are life sciences and pharma, precision technology, fintech and premium consumer. The Basel life-sciences corridor and the medtech and biotech clusters around Zurich and Lake Geneva feed a pipeline of drug-development and diagnostics companies that US specialist funds actively back, while Swiss precision-engineering and deep-tech firms fit industrial-technology mandates. A well-regarded fintech and crypto-adjacent scene around “Crypto Valley” adds further US-relevant stories. Because American investors reward clear comparables, a Swiss biotech or medtech company able to point to listed US peers can frame a valuation case that a domestic SIX listing might treat more conservatively.
Cross-border structuring from Switzerland
A Swiss AG group listing in the US can often use its Swiss holding company directly, since Swiss corporate structures are well understood by US counsel and auditors, or adopt a Luxembourg, Dutch or Irish topco where treaty and share-exchange efficiency argue for it. Switzerland imposes no exchange controls on an outbound listing, but the reorganisation engages Swiss federal and cantonal tax rulings, withholding tax and stamp-duty considerations, the Switzerland–US tax treaty, and PFIC analysis for US holders. Because Swiss cantonal tax practice varies, an advance ruling is common. These are structuring choices to settle with Swiss and US tax and securities counsel; Reverse Takeover arranges the transaction and does not provide legal or tax advice.
Audit and reporting readiness
Swiss companies report under Swiss Code of Obligations accounting, frequently supplemented by Swiss GAAP FER or IFRS at group level, so US readiness means presenting IFRS as issued by the IASB or US GAAP, audited to PCAOB standards by a PCAOB-registered firm. The major Swiss audit practices generally hold PCAOB registration, which helps availability, but building two or three years of restated, audited history and documenting internal controls to US expectations is typically the critical-path item. Engaging a PCAOB-registered auditor at the outset and scoping the conversion early usually determines the realistic timetable for the whole listing.
Choose a US venue
The same Switzerland company can target different US venues depending on its size and readiness. Each page below sets out the route and the listing standards.
- Nasdaq listingSwitzerland → Nasdaq
- NYSE American listingSwitzerland → NYSE American
- OTC Markets listingSwitzerland → OTC Markets
Exploring a US listing from Tell us about your company.
Start an enquiry →Reverse Takeover in Switzerland — frequently asked questions
Q1Can a Swiss AG list in the US without an offshore holding company?
Often, yes. Swiss holding structures are well understood by US market participants, so a Swiss AG can frequently serve as the listed parent, though a treaty-efficient European topco is sometimes preferred. The choice should be settled with Swiss and US counsel.
Q2Why is a Swiss tax ruling often mentioned for a US listing?
Swiss tax is administered cantonally, and practice varies, so groups commonly obtain an advance ruling to confirm the treatment of a reorganisation, withholding tax and stamp duty before proceeding. This is a matter for Swiss tax counsel; Reverse Takeover arranges the transaction and does not give tax advice.
Q3Do Swiss Code of Obligations or Swiss GAAP FER accounts need converting?
Yes. US-registered issuers present IFRS as issued by the IASB or US GAAP, audited under PCAOB standards. Swiss statutory accounts, and any Swiss GAAP FER or group IFRS, generally require restatement and re-audit by a PCAOB-registered firm, which is usually the critical-path item.
Q4Is Reverse Takeover a broker-dealer?
No. Reverse Takeover is an advisory and arranger — not a registered broker-dealer, investment adviser, law firm or audit firm. Regulated work is performed by the US securities counsel, PCAOB-registered auditors and transfer agents we coordinate.
Related markets
This page is general, educational information about listing routes and is not investment, legal, tax, or accounting advice, nor an offer or solicitation. Regulatory details change and vary by circumstance; obtain advice from qualified US securities counsel and your home-market advisers. See our disclosures.